Bone and Cancer
Bone and Cancer
Bone and CancerBone and Cancer Foundation, PO Box 287452 Bone and Cancer New York, NY 10128-0025  
Toll Free: 888 862-0999 Bone and Cancer Email: bcfdn@aol.com  
Bone and Cancer

Clinical Trials

Alphagan (brimonidine)

The following drug information is obtained from various newswires, published medical journal articles, and medical conference presentations.

Company:

Approval Status:

Approved September 1996

Specific Treatments:

open-angle glaucoma and ocular hypertension

Therapeutic Areas

General Information

Alphagan has been approved for the treatment of open-angle glaucoma and ocular hypertension.

Mechanism of Action

Alphagan is a selective alpha-2 agonist, which significantly lowers intraocular pressure with minimal effects on cardiovascular and pulmonary parameters. Its unique dual mechanism of action lowers intraocular pressure by reducing aqueous humor production and increasing uveoscleral outflow.

Additional Information

Glaucoma, an eye disease commonly characterized by excessive intraocular pressure, is a leading cause of blindness in the world.

 How To Order Publications:
  Glossary
  FAQ

Information About

Clinical Trials



 

 

 

 

 

 

 

 

 

 

 


 

 

 

 

 

 

 


  Copyright 2011 - The Bone and Cancer Foundation